Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on August 16, 2006
J Am Soc Nephrol 17: 2434-2442, 2006
© 2006 American Society of Nephrology
doi: 10.1681/ASN.2006020162

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2006020162v1
17/9/2434    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Price, P. M.
Right arrow Articles by Megyesi, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Price, P. M.
Right arrow Articles by Megyesi, J.

Cell Biology

Dependence of Cisplatin-Induced Cell Death In Vitro and In Vivo on Cyclin-Dependent Kinase 2

Peter M. Price*,{dagger}, Fang Yu{dagger}, Philipp Kaldis{ddagger}, Eiman Aleem{ddagger}, Grazyna Nowak§, Robert L. Safirstein*,{dagger} and Judit Megyesi*,{dagger}

Departments of * Internal Medicine, {dagger} Physiology, and § Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, Arkansas; and {ddagger} Mouse Cancer Genetics Program, National Cancer Institute, Frederick, Maryland

Address correspondence to: Dr. Peter M. Price, Department of Medicine, University of Arkansas for Medical Sciences, VA Medical Center-Research Section, 4300 West 7th Street, Room GC 147, Little Rock, AR 72205. Phone: 501-257-4800; Fax: 501-257-4822; E-mail: PricePeterM{at}uams.edu

Received for publication February 21, 2006. Accepted for publication June 29, 2006.

Cisplatin is one of the most effective chemotherapeutics, but its usefulness is limited by its toxicity to normal tissues, including cells of the kidney proximal tubule. The purpose of these studies was to determine the mechanism of cisplatin cytotoxicity. It was shown in vivo that cisplatin administration induces upregulation of the gene for the p21 cyclin-dependent kinase (cdk) inhibitor in kidney cells. This protein is a positive effector on the fate of cisplatin-exposed renal tubule cells in vivo and in vitro; adenoviral transduction of p21 completely protected proximal tubule cells from cisplatin toxicity. Herein is reported that cdk2 inhibitory drugs protect kidney cells in vivo and in vitro, that transduction of kidney cells in vitro with dominant-negative cdk2 also protected, and that cdk2 knockout cells were resistant to cisplatin. The cdk2 knockout cells regained cisplatin sensitivity after transduction with wild-type cdk2. It is concluded that cisplatin cytotoxicity depends on cdk2 activation and that the mechanism of p21 protection is by direct inhibition of cdk2. This demonstrated the involvement of a protein that previously was associated with cell-cycle progression with pathways of apoptosis. It also was demonstrated that this pathway of cisplatin-induced cell death can be interceded in vivo to prevent nephrotoxicity.




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
M. Jiang and Z. Dong
Regulation and Pathological Role of p53 in Cisplatin Nephrotoxicity
J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 300 - 307.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
A. B. Sanz, B. Santamaria, M. Ruiz-Ortega, J. Egido, and A. Ortiz
Mechanisms of Renal Apoptosis in Health and Disease
J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1634 - 1642.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
F. Yu, J. Megyesi, and P. M. Price
Cytoplasmic initiation of cisplatin cytotoxicity
Am J Physiol Renal Physiol, July 1, 2008; 295(1): F44 - F52.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
D. Sheikh-Hamad
Cisplatin-induced cytoxicity: is the nucleus relevant?
Am J Physiol Renal Physiol, July 1, 2008; 295(1): F42 - F43.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
A. Weidemann, W. M. Bernhardt, B. Klanke, C. Daniel, B. Buchholz, V. Campean, K. Amann, C. Warnecke, M. S. Wiesener, K.-U. Eckardt, et al.
HIF Activation Protects From Acute Kidney Injury
J. Am. Soc. Nephrol., March 1, 2008; 19(3): 486 - 494.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
J. Lechner, N. A. Malloth, P. Jennings, D. Heckl, W. Pfaller, and T. Seppi
Opposing roles of EGF in IFN-{alpha}-induced epithelial barrier destabilization and tissue repair
Am J Physiol Cell Physiol, December 1, 2007; 293(6): C1843 - C1850.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
F. Yu, J. Megyesi, R. L. Safirstein, and P. M. Price
Involvement of the CDK2-E2F1 pathway in cisplatin cytotoxicity in vitro and in vivo
Am J Physiol Renal Physiol, July 1, 2007; 293(1): F52 - F59.
[Abstract] [Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP